Loading...

Author: Jeannie


C-Path and MitoAction Announce Data Sharing Agreement to Support Treatment Development in Mitochondrial Disease

TUCSON, Ariz., June 7, 2022 — Critical Path Institute (C-Path) and MitoAction today announced a joint collaboration to incorporate patient data for rare Read More


Evan’s incredible journey

Sarah McGee fell backwards, collapsing into the red armchair as her mind suffocated under the pressure. Having just returned from yet another brutal doctor’s appointment, her husband, Kelly, was...


Family that lost child to rare disease speaks out on day of recognition

(WNDU) – The last day of February is Rare Disease Day, a day aimed to raise awareness about rare diseases. “There are many millions of Americans that are currently...


My Daughter’s Rare Disease Was A Mystery For Years. Here’s How We Finally Got A Diagnosis.

“’Give her time and she’ll surely catch up,’ they said. ‘She’ll be fine.’ … When Dalia was 9, she lost her ability to walk, talk, eat, and breathe without...


Noah, 11, is the only child in the world with this type of rare disease

When little Noah Barlow came rushing into the world at 29 weeks and weighing just over one kilogram, his parents had no idea of the harrowing journey that lay...


TK2d Patient Voices Elevated at FDA

FOR RELEASE FRIDAY, FEB. 4 AT 11:30AM Mitochondrial Medicine Frontier Program at Children’s Hospital of Philadelphia (CHOP) have developed a...


CHOP Researchers Develop New Clinical Diagnostic Test to Identify Genetic Sources of Mitochondrial Disease

CHOP Researchers Develop New Clinical Diagnostic Test to Identify Genetic Sources of Mitochondrial Disease New test analyzes


The Metabolic Genetic Testing Market to witness the mobile health-oriented renaissance

The Metabolic Genetic Testing Market is likely to grow on a robust note in the next decade. The next decade would be seeing the integration of telehealth services with...


Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders

January 10, 2022 02:00 ET | Source: Khondrion Khondrion completes enrolment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and...